| 33.84 1.27 (3.9%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 53.83  |
1-year : | 65.27 |
| Resists | First : | 46.08 |
Second : | 55.88 |
| Pivot price | 37.94 |
|||
| Supports | First : | 30.23 |
Second : | 25.15 |
| MAs | MA(5) : | 33.88 |
MA(20) : | 40.14 |
| MA(100) : | 26.84 |
MA(250) : | 28.01 |
|
| MACD | MACD : | -1.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 10.4 |
D(3) : | 5.7 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 75 | Low : | 10.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KRRO ] has closed above bottom band by 22.2%. Bollinger Bands are 42.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 34.36 - 34.52 | 34.52 - 34.67 |
| Low: | 29.87 - 30.04 | 30.04 - 30.2 |
| Close: | 33.53 - 33.84 | 33.84 - 34.12 |
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Fri, 31 Oct 2025
Clear Street Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation - Nasdaq
Thu, 30 Oct 2025
Clear Street initiates Korro Bio stock with Buy rating, $93 price target - Investing.com
Mon, 27 Oct 2025
Korro Bio’s KRRO-110 Study: A Potential Game-Changer in Genetic Therapy - TipRanks
Thu, 23 Oct 2025
Will Korro Bio (NASDAQ:KRRO) Spend Its Cash Wisely? - simplywall.st
Wed, 17 Sep 2025
Korro Bio’s SWOT analysis: RNA editing pioneer’s stock faces pivotal phase - Investing.com
Tue, 26 Aug 2025
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5.74e+006 (%) |
| Held by Institutions | 6.1 (%) |
| Shares Short | 1,480 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.398e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 863.1 % |
| Return on Equity (ttm) | -28.7 % |
| Qtrly Rev. Growth | 6.28e+006 % |
| Gross Profit (p.s.) | 0.51 |
| Sales Per Share | 0.51 |
| EBITDA (p.s.) | -9.74 |
| Qtrly Earnings Growth | -9.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 65.92 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.06e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|